5 Biotech/ Healthcare Stocks – ELX, EXL, PSQ, MSB And RHC

5 Biotech/ Healthcare Stocks - ELX, EXL, PSQ, MSB And RHC

Ellex Medical Lasers Ltd

Losses Narrowed in 1H 2019: Ellex Medical Lasers Ltd (ASX: ELX), eye disease equipment manufacturer, for the first half of FY 19, has reported 9% growth in the group revenue to $41.6 million on the back of 18% rise in the glaucoma therapy segment. There has been a 12% rise in the group EBITDA loss to $0.85 million compared to pcp driven by a 53% rise in the EBITDA of Lasers & Ultrasound segment. This is despite the rise in the expenditure of glaucoma and iAMD disease segments. As a result, the reported loss declined by 0.35% to $2.7million. Additionally, ELX for FY19 expects to grow its group revenue as well as anticipates improved EBITDA. The company’s operating cash flow is negative (-$1.8million) and has increased compared to -$0.5 million in the previous corresponding period, due to a rise in the working capital. Meanwhile, ELX stock has fallen 16.18% in three months as on March 8, 2019. The stock last traded at A$0.580 (as on 8 March 2019), up by 1.754% from its previous close.

Elixinol Global Ltd

Turnaround to Profit in FY 18: Elixinol Global Ltd (ASX: EXL) stock has risen 65.22 in three months as on March 8th, 2019 after the company, for FY 18 had reported a whopping increase of 121% in the group revenue driven by strong sales performance by Elixinol. The company’s Underlying EBITDA improved to $0.7m in FY2018 versus breakeven in FY2017. As a result, Underlying NPAT grew to $0.7m in FY2018 compared to a loss of $1.9m in FY2017. Additionally, the company expects to commission Elixinol’s Louisville facility, during the first half of FY2019, after which the current production capacity, will increase to more than double. Meanwhile, EXL’s stock is trading at the price of level $3.280 (as on 8 March 2019), down by 4.094% from its previous close.

Pacific Smiles Group Ltd

Reduced projection for EBITDA growth in FY 19: Pacific Smiles Group Ltd (ASX: PSQ) stock has fallen 11.76% in three months as on March 7th, 2019 after the company as per the revised outlook for FY 19 has reduced the projection for EBITDA growth to be approximately 5% on FY 2018 compared to the previous forecast of at least 10%. However, the company for FY 19, expects the growth in Patient Fee to be in the range of 12-15% on FY 2018 compared to the previous anticipation of 10-15%. Further, for FY 19, the company expects the growth Same Centre Patient Fee to be greater than 5%. PSQ closed the day’s session at A$1.215 and is trading at a P/E of 23.08x as on 8 March 2019.

Mesoblast limited

Turnaround to Loss in 1H FY 19: Mesoblast limited (ASX: MSB) stock has fallen 25.23% in six months as on March 7th, 2019 after the company for the first half FY 19 has reported the loss after tax of US$44.1 million compared to a profit after tax of US$6.7 million. This is on back of the investment done by the company in commercial manufacturing of US$8.0 million for getting GVHD approval, and also due to an increase in finance costs of US$5.1 million. The company’s revenue has fallen slightly to US$13.5 million during the first half FY19, compared with US$14.6 million in the corresponding period. However, for 1H FY 19, there is 50% decline in net operating cash outflows to US$17.5 million on the back of the timing of receipts of milestone payments. Additionally, MSB plans to start BLA filing, after the FDA meeting in April 2019, for getting marketing authorization of remestemcel-L. Meanwhile MSB stock is trading at the price of level $1.22 as on 8 March 2019. The share price has increased by 4.68% in last one month.

Ramsay Health Care Limited

Decent Performance in the First Half of FY 19: Ramsay Health Care Limited (ASX: RHC) stock has risen 14.46% in last three months as on March 8th, 2019 after the company. For 1H FY 19, the company has reported 1% rise in Core NPAT to $290.8 million & 9.6% rise in statutory net profit after tax to $270.1 million. During 1H FY 19, revenue rose by 14.9% to $5.1 billion & EBITDA increased by 9.8% (EBITDAR by 12%) to $728.6 million. Excluding Capio, RHC for half year 2019 has reported 6.1% rise in revenue and 7.2% increase in EBITDA (EBITDAR by 7.2%). Capio has led to 25.7% rise in revenue 19.1% increase in EBITDAR. Further, RHC for FY 19 has reaffirmed its guidance, & expects its Core EPS to grow up to 2%, comprising of Capio. Additionally, RHC has declared 4.3% rise in the fully-franked interim dividend to 60 cents on the previous corresponding period. Meanwhile RHC stock is trading at the price of $63.520 as on 8 March 2019.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.